20:43 , Nov 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma Mouse studies suggest dual inhibition of MCL1 and MEK could help treat KRAS-mutant adenocarcinoma. In seven patient-derived xenograft (PDX) mouse models of KRAS-mutant adenocarcinoma, the MCL1 inhibitor AMG 176 plus the MEK inhibitor...